Hospital news, December 2017
Chief Executive Steffan Crausaz is stepping down as Chief Executive in early 2018.
Transcript of video
Welcome to this edition of Hospital News.
I know many of you, like the PHARMAC team, are extremely busy getting ready for the end of the year.
By now, you’ve probably heard news about my departure from PHARMAC. I’ve been humbled by the experience of being here, being able to contribute to the excellent work of the New Zealand health system, and working with all of you, our partners across the system.
I’m delighted to that Sarah Fitt will be PHARMAC’s new Chief Executive, taking up the role in early January. Sarah is well known through the sector, she’s an exceptional leader both in the areas of management and clinical leadership, and she’ll do an outstanding job. So, while it’s sad to be going, I have complete faith that PHARMAC is being left in the most capable of hands.
In the last edition, I introduced our three aspirational bold goals. This edition gives some updates on the progress we’ve already made on these goals.
Also in this issue, we’ve got details of the bulk fluids Request for Proposals (RFP) competitive process. We’ve also got some information on expenditure across DHBs on the top 20 medicines being used.
In closing, I want to wish all of you a relaxing and happy festive season. Enjoy the new year and I wish you all the best for the future in continuing to work with PHARMAC.
In the last issue, we introduced a key part of our strategy – three aspirational goals that are designed to deliver significant health outcomes for all New Zealanders. Our first bold goal is to eliminate inequities in access to medicines by 2025.
This bold goal reflects a significantly expanded area of emphasis for PHARMAC. We have established a new team to progress this work. The team is leading further work to better understand what barriers Māori and other under-served groups, including those facing inequities or health disparities, face in accessing and using medicine.
Equity issues are at the heart of two of our strategies: Te Whaioranga, our Māori responsiveness strategy, and our Pacific Responsiveness Strategy. We expect the access equity work programme will complement these strategies, and we look forward to updating you as further progress is made.
We are also progressing work on bold goal two, which is to generate savings from medical device management to reinvest in health outcomes for New Zealanders. The Statement of Intent has more detail on our bold goals.
As of 1 December 2017, the Pharmaceutical Schedule includes around 69,000 line items from 39 suppliers. These contracts cover approximately $155 million to $165 million of annual expenditure.
We have released an RFP for the supply of permanent coronary drug-eluting stents to DHB hospitals under a market share procurement model. DHBs currently spend approximately $8 million per year on drug eluting stents.
We’re on track to bring half of the intended full scope of hospital medical devices under PHARMAC agreements before the end of 2018.
We have delayed making a decision on our bulk fluids proposal, which we issued for consultation in October 2017. Our proposed outcome was developed following a Request for Tenders for intravenous fluid bags and a range of irrigation solutions, collectively referred to as bulk fluids.
Consultation on this proposal has now closed, and we have received many detailed responses. The responses covered a range of topics, particularly around product suitability, sustainability and some of the products proposed for delisting.
We have determined that we need more time to:
- carefully consider the responses
- decide if we need further advice from our Clinical Advisory Group; and
- engage more with affected DHB Hospitals.
As a result, the changes proposed from 1 February 2018 will not occur on that date. PHARMAC expects a decision to be made, and subsequently notified, on the proposal early in 2018.
We’d like to thank everyone who took the time to provide feedback.
If you have any questions, please email Andrew Park, Senior Therapeutic Group Manager at email@example.com
PHARMAC has approved individual agreements with Ecomed Trading Pty Ltd (“Ecomed”) and Pharmaco (NZ) Ltd (“Pharmaco”) for the supply of medical thermometer products.
Post-menopausal women with early breast cancer will soon be able to have funded zoledronic acid, to prevent the disease spreading into bones.
Our Year in Review 2017 has been published, highlighting our work and medicine funding issues over the past year. It also includes data on pharmaceutical usage dating back more than 20 years.
Last updated: 15 August 2019